Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1996-04

AUTHORS

O. G. Kolterman, S. Schwartz, C. Corder, B. Levy, L. Klaff, J. Peterson, A. Gottlieb

ABSTRACT

Individuals with insulin-dependent diabetes mellitus (IDDM or type 1 diabetes) are deficient in both insulin and amylin, peptides secreted by the beta cell. We have investigated the effects of amylin replacement therapy employing the human amylin analogue, pramlintide (25, 28, 29-pro-human amylin, previously referred to as AC137), upon the responses to a standardized insulin infusion (40 mU. kg-1. h-1) for 100 min and a liquid Sustacal meal (360 kcal) in 84 healthy IDDM patients. Following baseline evaluations, patients were randomly assigned to receive subcutaneous injections of placebo, 30, 100 or 300 micrograms pramlintide 30 min before meals for 14 days. There was no meaningful difference between adverse events reported by the 30-micrograms pramlintide and the placebo groups, but ten subjects withdrew due to nausea, eight of these in the 300-micrograms dose group. Peak plasma pramlintide concentrations for the 30-micrograms group were 21 +/- 3 and 29 +/- 5 pmol/l on Days 1 and 14, respectively. These values are similar to postprandial plasma amylin concentrations in normal volunteers. The plasma glucose, free insulin, glucagon, epinephrine and norepinephrine concentrations during the insulin infusion test before and after therapy were identical in each of the group. Prior to pramlintide therapy, Sustacal ingestion produced a 4.0-4.8 mmol/l rise in plasma glucose concentrations in each of the groups. Pramlintide therapy reduced postprandial hyperglycaemia as reflected by the 3-h incremental AUCglucose (AUCglucose above or below fasting glucose concentration) Day 1 vs Day 14: 30 micrograms, 322 +/- 92 vs -38 +/- 161 mmol/l.min, p = 0.010; 100 micrograms, 317 +/- 92 vs -39 +/- 76 mmol/l.min, p = 0.001; and 300 micrograms, 268 +/- 96 vs -245 +/- 189 mmol/l.min, p = 0.077. Thus, pramlintide therapy with these regimens did not appear to impair either in vivo insulin action or the counter-regulatory response to hypoglycaemia but did show a clear effect of blunting postprandial hyperglycaemia following a standardized meal. More... »

PAGES

492-499

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf00400683

DOI

http://dx.doi.org/10.1007/bf00400683

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1010562990

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/8778001


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Amyloid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Analysis of Variance", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Glucose", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diabetes Mellitus, Type 1", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Eating", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypoglycemic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infusions, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Injections, Subcutaneous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Insulin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Islet Amyloid Polypeptide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Placebos", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418152.b", 
          "name": [
            "Amylin Pharmaceuticals, Inc., 9373 Towne Centre Drive, 92121, San Diego, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kolterman", 
        "givenName": "O. G.", 
        "id": "sg:person.0612636740.83", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0612636740.83"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Diabetes & Glandular Disease Clinic", 
          "id": "https://www.grid.ac/institutes/grid.418418.0", 
          "name": [
            "Diabetes and Glandular Disease Clinic, San Antonio, Texas, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schwartz", 
        "givenName": "S.", 
        "id": "sg:person.012101272322.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012101272322.91"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Oklahoma Medical Research Foundation", 
          "id": "https://www.grid.ac/institutes/grid.274264.1", 
          "name": [
            "Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Corder", 
        "givenName": "C.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "National Medical Research Corporation, Hartford, Connecticut, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Levy", 
        "givenName": "B.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Ranier Clinical Research Center, Renton, Washington, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Klaff", 
        "givenName": "L.", 
        "id": "sg:person.0735444751.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0735444751.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418152.b", 
          "name": [
            "Amylin Pharmaceuticals, Inc., 9373 Towne Centre Drive, 92121, San Diego, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Peterson", 
        "givenName": "J.", 
        "id": "sg:person.01301636770.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301636770.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418152.b", 
          "name": [
            "Amylin Pharmaceuticals, Inc., 9373 Towne Centre Drive, 92121, San Diego, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gottlieb", 
        "givenName": "A.", 
        "id": "sg:person.0673343117.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673343117.64"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1073/pnas.85.20.7763", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006142362"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00403371", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009939773", 
          "https://doi.org/10.1007/bf00403371"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00403371", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009939773", 
          "https://doi.org/10.1007/bf00403371"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00403371", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009939773", 
          "https://doi.org/10.1007/bf00403371"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.84.23.8628", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010355010"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00401833", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010472397", 
          "https://doi.org/10.1007/bf00401833"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00401833", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010472397", 
          "https://doi.org/10.1007/bf00401833"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00401833", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010472397", 
          "https://doi.org/10.1007/bf00401833"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0140-6736(92)90785-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010789135"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0140-6736(92)90785-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010789135"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1172/jci111519", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015733242"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0006-291x(86)90708-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016165956"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00400569", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019893221", 
          "https://doi.org/10.1007/bf00400569"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00400569", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019893221", 
          "https://doi.org/10.1007/bf00400569"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00400569", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019893221", 
          "https://doi.org/10.1007/bf00400569"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm198303033080903", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021145684"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1651-2227.1993.tb12669.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023585236"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00404025", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031992201", 
          "https://doi.org/10.1007/bf00404025"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00404025", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031992201", 
          "https://doi.org/10.1007/bf00404025"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00404025", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031992201", 
          "https://doi.org/10.1007/bf00404025"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diab.39.6.752", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033145490"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jcb.240550003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036886307"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jcb.240550003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036886307"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diab.39.5.639", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041468733"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1677/joe.0.124r009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042042276"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00400094", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052810677", 
          "https://doi.org/10.1007/bf00400094"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00400094", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052810677", 
          "https://doi.org/10.1007/bf00400094"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00400094", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052810677", 
          "https://doi.org/10.1007/bf00400094"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1055/s-2007-1003759", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1057478338"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1210/jc.78.5.1257", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064297443"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1210/jcem.78.5.8175987", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064318706"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1210/mend-3-11-1775", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064330414"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diab.28.12.1039", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070733421"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diacare.18.8.1179", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070746815"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079958582", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1080356418", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081993197", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082450201", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082740325", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1996-04", 
    "datePublishedReg": "1996-04-01", 
    "description": "Individuals with insulin-dependent diabetes mellitus (IDDM or type 1 diabetes) are deficient in both insulin and amylin, peptides secreted by the beta cell. We have investigated the effects of amylin replacement therapy employing the human amylin analogue, pramlintide (25, 28, 29-pro-human amylin, previously referred to as AC137), upon the responses to a standardized insulin infusion (40 mU. kg-1. h-1) for 100 min and a liquid Sustacal meal (360 kcal) in 84 healthy IDDM patients. Following baseline evaluations, patients were randomly assigned to receive subcutaneous injections of placebo, 30, 100 or 300 micrograms pramlintide 30 min before meals for 14 days. There was no meaningful difference between adverse events reported by the 30-micrograms pramlintide and the placebo groups, but ten subjects withdrew due to nausea, eight of these in the 300-micrograms dose group. Peak plasma pramlintide concentrations for the 30-micrograms group were 21 +/- 3 and 29 +/- 5 pmol/l on Days 1 and 14, respectively. These values are similar to postprandial plasma amylin concentrations in normal volunteers. The plasma glucose, free insulin, glucagon, epinephrine and norepinephrine concentrations during the insulin infusion test before and after therapy were identical in each of the group. Prior to pramlintide therapy, Sustacal ingestion produced a 4.0-4.8 mmol/l rise in plasma glucose concentrations in each of the groups. Pramlintide therapy reduced postprandial hyperglycaemia as reflected by the 3-h incremental AUCglucose (AUCglucose above or below fasting glucose concentration) Day 1 vs Day 14: 30 micrograms, 322 +/- 92 vs -38 +/- 161 mmol/l.min, p = 0.010; 100 micrograms, 317 +/- 92 vs -39 +/- 76 mmol/l.min, p = 0.001; and 300 micrograms, 268 +/- 96 vs -245 +/- 189 mmol/l.min, p = 0.077. Thus, pramlintide therapy with these regimens did not appear to impair either in vivo insulin action or the counter-regulatory response to hypoglycaemia but did show a clear effect of blunting postprandial hyperglycaemia following a standardized meal.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/bf00400683", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1001482", 
        "issn": [
          "0012-186X", 
          "1432-0428"
        ], 
        "name": "Diabetologia", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "39"
      }
    ], 
    "name": "Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM", 
    "pagination": "492-499", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "3252901627ef80593d7e9bbd60a7c4020110b8e934dce87abdc1a87604b62fa7"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "8778001"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "0006777"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf00400683"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1010562990"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf00400683", 
      "https://app.dimensions.ai/details/publication/pub.1010562990"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T14:00", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000371_0000000371/records_130829_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/BF00400683"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf00400683'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf00400683'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf00400683'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf00400683'


 

This table displays all metadata directly associated to this object as RDF triples.

272 TRIPLES      21 PREDICATES      74 URIs      39 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf00400683 schema:about N010e481a414247e482e52ef6a3bf22eb
2 N0384a3b95c694647a61fca89257de16f
3 N21f08b1658344b6c98414615eedd6cd3
4 N2f714653b79c414bb9aca2639ba5d8f8
5 N32ff6194d504469ab447b5acf9f501e5
6 N42e526806cf544329bb3789000360553
7 N5d949d82f5d64bca86ed6025b2a2bdd5
8 N742d633fff084172a29695500001f79d
9 N74e7d754cb1945cdb82b38f30b0a67d1
10 N7b3e92750a524354abec5c65b1ce282c
11 N81cfc85fca654cf3aed7252ba16408d7
12 N8c61030b7f2943f5b8f50e8a9693b6c8
13 N8d9d68b1895b43cfa68fcc97810b29f5
14 N9d68c19417274130a27a7d4ddb42bd1b
15 Na42001c0628e4a89898d4fd6b41aa371
16 Nefffae6d3f8941f98c00f4bc9db99c12
17 Nf5ec85fa56d74724bfafb440c0b1ba94
18 Nf6c9dfdfed114e528abeb1d7bb80a3da
19 anzsrc-for:11
20 anzsrc-for:1103
21 schema:author N735d5d0a3811469fbc568870347d321f
22 schema:citation sg:pub.10.1007/bf00400094
23 sg:pub.10.1007/bf00400569
24 sg:pub.10.1007/bf00401833
25 sg:pub.10.1007/bf00403371
26 sg:pub.10.1007/bf00404025
27 https://app.dimensions.ai/details/publication/pub.1079958582
28 https://app.dimensions.ai/details/publication/pub.1080356418
29 https://app.dimensions.ai/details/publication/pub.1081993197
30 https://app.dimensions.ai/details/publication/pub.1082450201
31 https://app.dimensions.ai/details/publication/pub.1082740325
32 https://doi.org/10.1002/jcb.240550003
33 https://doi.org/10.1016/0006-291x(86)90708-4
34 https://doi.org/10.1016/0140-6736(92)90785-2
35 https://doi.org/10.1055/s-2007-1003759
36 https://doi.org/10.1056/nejm198303033080903
37 https://doi.org/10.1073/pnas.84.23.8628
38 https://doi.org/10.1073/pnas.85.20.7763
39 https://doi.org/10.1111/j.1651-2227.1993.tb12669.x
40 https://doi.org/10.1172/jci111519
41 https://doi.org/10.1210/jc.78.5.1257
42 https://doi.org/10.1210/jcem.78.5.8175987
43 https://doi.org/10.1210/mend-3-11-1775
44 https://doi.org/10.1677/joe.0.124r009
45 https://doi.org/10.2337/diab.28.12.1039
46 https://doi.org/10.2337/diab.39.5.639
47 https://doi.org/10.2337/diab.39.6.752
48 https://doi.org/10.2337/diacare.18.8.1179
49 schema:datePublished 1996-04
50 schema:datePublishedReg 1996-04-01
51 schema:description Individuals with insulin-dependent diabetes mellitus (IDDM or type 1 diabetes) are deficient in both insulin and amylin, peptides secreted by the beta cell. We have investigated the effects of amylin replacement therapy employing the human amylin analogue, pramlintide (25, 28, 29-pro-human amylin, previously referred to as AC137), upon the responses to a standardized insulin infusion (40 mU. kg-1. h-1) for 100 min and a liquid Sustacal meal (360 kcal) in 84 healthy IDDM patients. Following baseline evaluations, patients were randomly assigned to receive subcutaneous injections of placebo, 30, 100 or 300 micrograms pramlintide 30 min before meals for 14 days. There was no meaningful difference between adverse events reported by the 30-micrograms pramlintide and the placebo groups, but ten subjects withdrew due to nausea, eight of these in the 300-micrograms dose group. Peak plasma pramlintide concentrations for the 30-micrograms group were 21 +/- 3 and 29 +/- 5 pmol/l on Days 1 and 14, respectively. These values are similar to postprandial plasma amylin concentrations in normal volunteers. The plasma glucose, free insulin, glucagon, epinephrine and norepinephrine concentrations during the insulin infusion test before and after therapy were identical in each of the group. Prior to pramlintide therapy, Sustacal ingestion produced a 4.0-4.8 mmol/l rise in plasma glucose concentrations in each of the groups. Pramlintide therapy reduced postprandial hyperglycaemia as reflected by the 3-h incremental AUCglucose (AUCglucose above or below fasting glucose concentration) Day 1 vs Day 14: 30 micrograms, 322 +/- 92 vs -38 +/- 161 mmol/l.min, p = 0.010; 100 micrograms, 317 +/- 92 vs -39 +/- 76 mmol/l.min, p = 0.001; and 300 micrograms, 268 +/- 96 vs -245 +/- 189 mmol/l.min, p = 0.077. Thus, pramlintide therapy with these regimens did not appear to impair either in vivo insulin action or the counter-regulatory response to hypoglycaemia but did show a clear effect of blunting postprandial hyperglycaemia following a standardized meal.
52 schema:genre research_article
53 schema:inLanguage en
54 schema:isAccessibleForFree false
55 schema:isPartOf N198ac8eaeee74bb892da5ac865bd0dde
56 Nec7a23aefae94eb498481d98a4cdbe28
57 sg:journal.1001482
58 schema:name Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM
59 schema:pagination 492-499
60 schema:productId N302150428a9d4e7aade43415ebd9330e
61 N3bd4205147be4a169087d626969c549e
62 Na2fe19d533c2431f842befd76f17e0c1
63 Nbee836902ad94219949e8ab7e60fdf16
64 Nd585fb93081b4a1cbb53ceaa8a3683cd
65 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010562990
66 https://doi.org/10.1007/bf00400683
67 schema:sdDatePublished 2019-04-11T14:00
68 schema:sdLicense https://scigraph.springernature.com/explorer/license/
69 schema:sdPublisher Nb314e926787d4afca7f0e1d274eb7e4e
70 schema:url http://link.springer.com/10.1007/BF00400683
71 sgo:license sg:explorer/license/
72 sgo:sdDataset articles
73 rdf:type schema:ScholarlyArticle
74 N010e481a414247e482e52ef6a3bf22eb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Female
76 rdf:type schema:DefinedTerm
77 N0384a3b95c694647a61fca89257de16f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Adolescent
79 rdf:type schema:DefinedTerm
80 N0cdb4815d48b4badb0b65d18c0798150 rdf:first sg:person.0735444751.15
81 rdf:rest N59d1d6e981e540f3ba88321b59f4f48b
82 N198ac8eaeee74bb892da5ac865bd0dde schema:volumeNumber 39
83 rdf:type schema:PublicationVolume
84 N21f08b1658344b6c98414615eedd6cd3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Islet Amyloid Polypeptide
86 rdf:type schema:DefinedTerm
87 N2f714653b79c414bb9aca2639ba5d8f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Hypoglycemic Agents
89 rdf:type schema:DefinedTerm
90 N302150428a9d4e7aade43415ebd9330e schema:name nlm_unique_id
91 schema:value 0006777
92 rdf:type schema:PropertyValue
93 N32ff6194d504469ab447b5acf9f501e5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Adult
95 rdf:type schema:DefinedTerm
96 N33f3acf108b7480f843a612ff6cfd693 rdf:first sg:person.012101272322.91
97 rdf:rest N82c7572a4bb6423aa9e63f4509079a2f
98 N3bd4205147be4a169087d626969c549e schema:name dimensions_id
99 schema:value pub.1010562990
100 rdf:type schema:PropertyValue
101 N42e526806cf544329bb3789000360553 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Infusions, Intravenous
103 rdf:type schema:DefinedTerm
104 N59d1d6e981e540f3ba88321b59f4f48b rdf:first sg:person.01301636770.40
105 rdf:rest Nec59dd1497314f939de613d246a4dd81
106 N5d949d82f5d64bca86ed6025b2a2bdd5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Insulin
108 rdf:type schema:DefinedTerm
109 N6ec3bc9fc1f743779dd6ab184d1bed3c rdf:first Nccfa381323f64b748de03aa944c3da07
110 rdf:rest N0cdb4815d48b4badb0b65d18c0798150
111 N735d5d0a3811469fbc568870347d321f rdf:first sg:person.0612636740.83
112 rdf:rest N33f3acf108b7480f843a612ff6cfd693
113 N742d633fff084172a29695500001f79d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Middle Aged
115 rdf:type schema:DefinedTerm
116 N74e7d754cb1945cdb82b38f30b0a67d1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Humans
118 rdf:type schema:DefinedTerm
119 N7b3e92750a524354abec5c65b1ce282c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Amyloid
121 rdf:type schema:DefinedTerm
122 N81cfc85fca654cf3aed7252ba16408d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Male
124 rdf:type schema:DefinedTerm
125 N82c7572a4bb6423aa9e63f4509079a2f rdf:first Nede88c88445a44f9932ea21cf6cd70fb
126 rdf:rest N6ec3bc9fc1f743779dd6ab184d1bed3c
127 N8c61030b7f2943f5b8f50e8a9693b6c8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Blood Glucose
129 rdf:type schema:DefinedTerm
130 N8d9d68b1895b43cfa68fcc97810b29f5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Dose-Response Relationship, Drug
132 rdf:type schema:DefinedTerm
133 N9d68c19417274130a27a7d4ddb42bd1b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Diabetes Mellitus, Type 1
135 rdf:type schema:DefinedTerm
136 Na2fe19d533c2431f842befd76f17e0c1 schema:name readcube_id
137 schema:value 3252901627ef80593d7e9bbd60a7c4020110b8e934dce87abdc1a87604b62fa7
138 rdf:type schema:PropertyValue
139 Na42001c0628e4a89898d4fd6b41aa371 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Eating
141 rdf:type schema:DefinedTerm
142 Nb314e926787d4afca7f0e1d274eb7e4e schema:name Springer Nature - SN SciGraph project
143 rdf:type schema:Organization
144 Nbee836902ad94219949e8ab7e60fdf16 schema:name doi
145 schema:value 10.1007/bf00400683
146 rdf:type schema:PropertyValue
147 Nc96795e106af43d0b755bab6fb23d2c4 schema:name National Medical Research Corporation, Hartford, Connecticut, USA
148 rdf:type schema:Organization
149 Nccfa381323f64b748de03aa944c3da07 schema:affiliation Nc96795e106af43d0b755bab6fb23d2c4
150 schema:familyName Levy
151 schema:givenName B.
152 rdf:type schema:Person
153 Nd0fad44dda2f49a68014f85e4c891b19 schema:name Ranier Clinical Research Center, Renton, Washington, USA
154 rdf:type schema:Organization
155 Nd585fb93081b4a1cbb53ceaa8a3683cd schema:name pubmed_id
156 schema:value 8778001
157 rdf:type schema:PropertyValue
158 Nec59dd1497314f939de613d246a4dd81 rdf:first sg:person.0673343117.64
159 rdf:rest rdf:nil
160 Nec7a23aefae94eb498481d98a4cdbe28 schema:issueNumber 4
161 rdf:type schema:PublicationIssue
162 Nede88c88445a44f9932ea21cf6cd70fb schema:affiliation https://www.grid.ac/institutes/grid.274264.1
163 schema:familyName Corder
164 schema:givenName C.
165 rdf:type schema:Person
166 Nefffae6d3f8941f98c00f4bc9db99c12 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Injections, Subcutaneous
168 rdf:type schema:DefinedTerm
169 Nf5ec85fa56d74724bfafb440c0b1ba94 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Analysis of Variance
171 rdf:type schema:DefinedTerm
172 Nf6c9dfdfed114e528abeb1d7bb80a3da schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Placebos
174 rdf:type schema:DefinedTerm
175 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
176 schema:name Medical and Health Sciences
177 rdf:type schema:DefinedTerm
178 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
179 schema:name Clinical Sciences
180 rdf:type schema:DefinedTerm
181 sg:journal.1001482 schema:issn 0012-186X
182 1432-0428
183 schema:name Diabetologia
184 rdf:type schema:Periodical
185 sg:person.012101272322.91 schema:affiliation https://www.grid.ac/institutes/grid.418418.0
186 schema:familyName Schwartz
187 schema:givenName S.
188 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012101272322.91
189 rdf:type schema:Person
190 sg:person.01301636770.40 schema:affiliation https://www.grid.ac/institutes/grid.418152.b
191 schema:familyName Peterson
192 schema:givenName J.
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301636770.40
194 rdf:type schema:Person
195 sg:person.0612636740.83 schema:affiliation https://www.grid.ac/institutes/grid.418152.b
196 schema:familyName Kolterman
197 schema:givenName O. G.
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0612636740.83
199 rdf:type schema:Person
200 sg:person.0673343117.64 schema:affiliation https://www.grid.ac/institutes/grid.418152.b
201 schema:familyName Gottlieb
202 schema:givenName A.
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673343117.64
204 rdf:type schema:Person
205 sg:person.0735444751.15 schema:affiliation Nd0fad44dda2f49a68014f85e4c891b19
206 schema:familyName Klaff
207 schema:givenName L.
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0735444751.15
209 rdf:type schema:Person
210 sg:pub.10.1007/bf00400094 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052810677
211 https://doi.org/10.1007/bf00400094
212 rdf:type schema:CreativeWork
213 sg:pub.10.1007/bf00400569 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019893221
214 https://doi.org/10.1007/bf00400569
215 rdf:type schema:CreativeWork
216 sg:pub.10.1007/bf00401833 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010472397
217 https://doi.org/10.1007/bf00401833
218 rdf:type schema:CreativeWork
219 sg:pub.10.1007/bf00403371 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009939773
220 https://doi.org/10.1007/bf00403371
221 rdf:type schema:CreativeWork
222 sg:pub.10.1007/bf00404025 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031992201
223 https://doi.org/10.1007/bf00404025
224 rdf:type schema:CreativeWork
225 https://app.dimensions.ai/details/publication/pub.1079958582 schema:CreativeWork
226 https://app.dimensions.ai/details/publication/pub.1080356418 schema:CreativeWork
227 https://app.dimensions.ai/details/publication/pub.1081993197 schema:CreativeWork
228 https://app.dimensions.ai/details/publication/pub.1082450201 schema:CreativeWork
229 https://app.dimensions.ai/details/publication/pub.1082740325 schema:CreativeWork
230 https://doi.org/10.1002/jcb.240550003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036886307
231 rdf:type schema:CreativeWork
232 https://doi.org/10.1016/0006-291x(86)90708-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016165956
233 rdf:type schema:CreativeWork
234 https://doi.org/10.1016/0140-6736(92)90785-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010789135
235 rdf:type schema:CreativeWork
236 https://doi.org/10.1055/s-2007-1003759 schema:sameAs https://app.dimensions.ai/details/publication/pub.1057478338
237 rdf:type schema:CreativeWork
238 https://doi.org/10.1056/nejm198303033080903 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021145684
239 rdf:type schema:CreativeWork
240 https://doi.org/10.1073/pnas.84.23.8628 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010355010
241 rdf:type schema:CreativeWork
242 https://doi.org/10.1073/pnas.85.20.7763 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006142362
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1111/j.1651-2227.1993.tb12669.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1023585236
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1172/jci111519 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015733242
247 rdf:type schema:CreativeWork
248 https://doi.org/10.1210/jc.78.5.1257 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064297443
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1210/jcem.78.5.8175987 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064318706
251 rdf:type schema:CreativeWork
252 https://doi.org/10.1210/mend-3-11-1775 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064330414
253 rdf:type schema:CreativeWork
254 https://doi.org/10.1677/joe.0.124r009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042042276
255 rdf:type schema:CreativeWork
256 https://doi.org/10.2337/diab.28.12.1039 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070733421
257 rdf:type schema:CreativeWork
258 https://doi.org/10.2337/diab.39.5.639 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041468733
259 rdf:type schema:CreativeWork
260 https://doi.org/10.2337/diab.39.6.752 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033145490
261 rdf:type schema:CreativeWork
262 https://doi.org/10.2337/diacare.18.8.1179 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070746815
263 rdf:type schema:CreativeWork
264 https://www.grid.ac/institutes/grid.274264.1 schema:alternateName Oklahoma Medical Research Foundation
265 schema:name Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA
266 rdf:type schema:Organization
267 https://www.grid.ac/institutes/grid.418152.b schema:alternateName AstraZeneca (United States)
268 schema:name Amylin Pharmaceuticals, Inc., 9373 Towne Centre Drive, 92121, San Diego, CA, USA
269 rdf:type schema:Organization
270 https://www.grid.ac/institutes/grid.418418.0 schema:alternateName Diabetes & Glandular Disease Clinic
271 schema:name Diabetes and Glandular Disease Clinic, San Antonio, Texas, USA
272 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...